CRISPR Gene Editing Technique Featured in Upcoming Myeloma Immunotherapy Trial
A Phase 1 clinical trial that uses the gene editing tool CRISPR to engineer multiple myeloma cellular immunotherapy will soon be underway at the…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
FDA to Give Priority Review to Darzalex Combinations for Multiple Myeloma
The U.S. Food and Drug Admnistration will give priority review to Darzalex (daratumumab) as an add-on to standard treatments for multiple myeloma patients who cannot…
Researchers Find Faster, Better Approach to Harvesting Stem Cells for Bone Marrow Transplants, Mouse Study Suggests
A single injection of a new drug combination leads to faster and more effective harvesting of blood stem cells from bone marrow donors, a new mouse…
First Patient Dosed in Phase 1 Trial of P-BCMA-101 CAR T-Cell Therapy for Multiple Myeloma
The first patient has been dosed in a Phase 1 trial of P-BCMA-101, a new, more powerful type of CAR T-cell therapy to fight multiple…
Gamida Recruiting Myeloma Patients for Phase 1 Trial of Its Killer Cells-based Therapy
Gamida Cell is enrolling participants in a Phase 1 clinical trial of an immunotherapy for myeloma and non-Hodgkin’s lymphoma that is based on expanding the…
Potential Myeloma Therapy Shows Positive Interim Phase 2 Trial Results, According to Report
Molecular Partners‘ multiple myeloma treatment candidate MP0250 showed positive preliminary safety and effectiveness results in an ongoing Phase 2 clinical study, according to the biopharmaceutical…
